Search All News
Congratulations to our Dr. Markus Siegelin, one of the four Columbia University cancer researchers who have been awarded for their innovative, life-changing cancer research.
Dr. Lin is one of the two recipients of the 2022 Early Career Development Pilot Grant, awarded by the Herbert Irving Comprehensive Cancer Center (HICCC).
Pathology faculty member, Dr. Peter Canoll, is the co-principal investigator on one of the three multi-disciplinary research teams awarded the grant.
Source:HICCC NewsAugust 2, 2021
Laura Pasqualucci, MD and Yee Won Yang, PhD are among the five Columbia University cancer researchers named 2020 Velocity Fellows.
Source:HICCC NewsMay 3, 2021
A new study, lead by Dr. Kevin Gardner, highlights a prognostic biomarker called Kaiso that may provide some insight into the biological reasons for racial disparities in breast cancer.
Source:Journal of Clinical PathwaysOctober 8, 2020
Expanded genomic panel testing was clinically impactful in most patients with high-risk cancer, yet payers reimbursed only 10.75% of the charge on average, if reimbursed at all, new study found.
Source:Zuckerman InstituteMay 1, 2020
Findings provide new insight into the link between seizures and tumor progression; can help develop improved diagnostics and treatments for deadly form of brain cancer
- January 16, 2020
In this study, the authors reported on a single-institution experience on 3-year prospective PSCPC regarding risk of malignancy (ROM) and the overall risk of malignancy (OROM).
Source:HICCC NewsSeptember 4, 2019
Piero Dalerba, MD is one of the six inaugural Velocity fellows, whose innovative research projects to solve cancer are being funded by the money raised from the Velocity ride.
Source:CUMC NewsroomJuly 12, 2019
Piero Dalerba and Teresa M. Palomero Vazquez of Pathology share the award with four other Columbia cancer researchers
- May 24, 2019
Swarnali Acharyya has been named a 2019 Schaefer Research Scholar for her study on identifying the mechanisms of brain metastasis.
Source:Wiley Online LibraryMarch 8, 2019
Fusobacterium nucleatum, a Gram‐negative oral anaerobe, is a significant contributor to colorectal cancer.